<?xml version="1.0" encoding="UTF-8"?>
<p id="Par111">Considering that the new treatments actually guarantee an increase in survival, a further positive effect could be achieved by strengthening the supportive treatments to combat these infections; this would allow obtaining better tolerability of the aggressive therapeutic regimens these patients undergo [
 <xref ref-type="bibr" rid="CR2">2</xref>]. The major limitation of this review is that reported results stem from few cases, often with limited significance. However, it is confirmed that respiratory viral infections continue to cause disease in both the pre- and post-transplant period; in the event of an onset in the pre-transplant period, it is advisable to delay the transplant, but there are no clear indications in this regard. Deferral of take in charge, although it could be the most reasonable choice, is not always feasible, especially in the presence of conditions such as important lymphopenia or persistent aplasia [
 <xref ref-type="bibr" rid="CR50">50</xref>].
</p>
